Nutra Pharma posted a net loss of $3.95 million for the quarter ended June 30, 2026, swinging from net income of $369,577.
Net sales fell 59.23% to $34,463 versus the prior-year quarter, reflecting product lines transitioned to Avini Health and lower private-label orders.
Operating expenses rose 32.24% to $468,089 on higher consulting and professional fees tied to SEC filing and tax-return catch-up work.
Derivative-related fair-value changes produced a $3.41 million loss, versus a $704,622 gain a year earlier, as hybrid-instrument liabilities fluctuated.
NPHC•
